Login to Your Account



J&J's guselkumab sails onward, besting Humira in second phase III

By Michael Fitzhugh
Staff Writer

Friday, March 3, 2017

Johnson & Johnson's anti-interleukin 23 candidate, guselkumab, has outperformed Abbvie Inc.'s Humira in a second pivotal plaque psoriasis trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription